Diligence memo · auto-generated · as of July 2, 2026
Edison Pharmaceuticals Inc
Edison Pharmaceuticals Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Edison Pharmaceuticals Inc operates in Biotechnology, based in MOUNTAIN VIEW.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Edison Pharmaceuticals Inc has raised $80M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $50M on 2014-03-20.
Most recent recorded round closed around 2014-03-20.
Valuation (modeled)modeled
Provath models Edison Pharmaceuticals Inc at approximately $2.0B (range $155M–$5.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.90× the median modeled value of Series C Biotechnology companies in 2013–2015 (41 peers) — value vs value, same stage and era. Within the normal band (90% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 12.3 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 88% of Biotechnology peers (4293 compared).
Modeled value ranks above 95% of those peers.
Closest niche peers: Antigenics LLC/DE, Naurex Inc., Fluidigm Corp, Tengion Inc, Spark Therapeutics, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.